Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Entry Point for Hepatitis C Infection Identified

Editor's pick
University of Illinois press release
25 January 2012
New & experimental hepatitis C treatment

Vertex Vows to Fight On With Alios Drugs in High-Stakes Hepatitis C Race

Editor's pick
Xconomy
25 January 2012
New & experimental hepatitis C treatment

Achillion's Hep C Pipeline Likely Can't Compete

Editor's pick
BioMed Reports
19 January 2012
Pharmaceutical industry

Bristol-Myers Raised Offer 30% to Beat Competitor for Inhibitex

Editor's pick
Bloomberg Business Week
17 January 2012
New & experimental hepatitis C treatment

Idenix Reports Advancement of HCV Development Pipeline

Editor's pick
Idenix (press release)
11 January 2012
New & experimental hepatitis C treatment

Achillion Reports Clinical Data on Portfolio of HCV Protease Inhibitors

Editor's pick
Achillion (press release)
11 January 2012
Pharmaceutical industry

Merck Hepatitis C Drug May `Anchor' Future Worldwide Regimen

Editor's pick
Bloomberg
10 January 2012
Pharmaceutical industry

Bristol Buys Inhibitex for $2.5 Billion to Compete in Hepatitis

Editor's pick
Bloomberg BusinessWeek
9 January 2012
Pharmaceutical industry

The Hepatitis C Market: Biotech’s Version of the Daytona 500

Editor's pick
Xconomy
13 December 2011
New & experimental hepatitis C treatment

AASLD: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV

Editor's pick
HIVandHepatitis.com
12 December 2011
Pharmaceutical industry

Pharmasset Poised to Pay 20% With Gilead Deal Closing

Editor's pick
Bloomberg Businessweek
6 December 2011
New & experimental hepatitis C treatment

University launches iphone app for hepatitis treatment

Editor's pick
Eurekalert Medicine & Health
22 November 2011
Pharmaceutical industry

HIV Drug Giant Gilead Acquires Pharmasset, a Hep C Drug Development Leader

Editor's pick
AIDSMeds.com
21 November 2011
New & experimental hepatitis C treatment

Transgene’s Therapeutic HCV Vaccine TG4040 Combined with Commonly Used Treatment Achieves Substantial Viral Suppression in Randomized Phase II trial

Editor's pick
Transgene press release
8 November 2011
New & experimental hepatitis C treatment

All-Oral Treatment Regimen of Bristol-Myers Squibb’s Investigational NS5A and NS3 Inhibitors Achieved 90% Sustained Virologic Response (SVR12) in Phase II Study Sentinel Cohort of Genotype 1b Null Responders

Editor's pick
Bristol-Myers Squibb press release
8 November 2011
New & experimental hepatitis C treatment

Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment

Editor's pick
Boehringer Ingelheim press release
8 November 2011
New & experimental hepatitis C treatment

Novartis DEB025 data showed viral clearance as early as six weeks and potential for interferon-free therapy in hepatitis C patients

Editor's pick
Novartis (press release)
7 November 2011
New & experimental hepatitis C treatment

Positive Interim Data From a Phase 2 Study of INCIVEK(TM) (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting(R)

Editor's pick
Vertex (press release)
7 November 2011
New & experimental hepatitis C treatment

Twelve Weeks Interferon-Free PSI-7977 Regimen Cures 100 Percent Hep C Genotype 2/3

Editor's pick
AIDSMeds
6 November 2011
New & experimental hepatitis C treatment

Copy of Twelve Weeks Interferon-Free PSI-7977 Regimen Cures 100 Percent Hep C Genotype 2/3

Editor's pick
Kaiser Daily Global Health Policy Report
6 November 2011
New & experimental hepatitis C treatment

AASLD-Santaris Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week

Editor's pick
Santaris press release
5 November 2011
New & experimental hepatitis C treatment

Pharmasset rises on new hepatitis C drug studies

Editor's pick
Bloomberg BusinessWeek
2 November 2011
New & experimental hepatitis C treatment

TMC435-Based Therapy Significantly Improved Viral Cure Rates in Patients Who Failed Prior Treatment for Hepatitis C

Editor's pick
Business Wire
2 November 2011
New & experimental hepatitis C treatment

Pharmasset Takes Lead in Race to Develop Hep C Therapy By Pill

Editor's pick
The Street
1 November 2011